Infarct Size as Assessed by Peak Enzyme Levels is Reduced in Patients Who Are Using Angiotensin-Converting Enzyme Inhibitors at the Onset of Infarction

Author： Landmark K.   Aursnes I.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.20, Iss.6, 2000-12, pp. : 415-423

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Treatment with Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers or a Combination of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Low-Risk Patients after Acute Myocardial Infarction: The ABC Study

By  

Heart Drug, Vol. 1, Iss. 1, 2001-03 ,pp. : 20-25

Karger

Access to resources Recommend Favorite

Cost of Heart Failure in Patients Receiving -Blockers and Angiotensin-Converting Enzyme Inhibitors

By Weintraub W.S.  

Clinical Drug Investigation, Vol. 24, Iss. 5, 2004-01 ,pp. : 255-264

Adis International

Access to resources Recommend Favorite

Ongoing trials involving angiotensin-converting enzyme inhibitors

By Nadar Sunil   Lip Gregory YH  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1633-1643

Informa Healthcare

Access to resources Recommend Favorite

Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors

By  

Current Pharmaceutical Design, Vol. 21, Iss. 13, 2015-04 ,pp. : 1764-1775

Bentham Science Publishers

Access to resources Recommend Favorite

The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction

By Kvan Elena   Reikvam Aasmund  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 3, 2004-05 ,pp. : 205-210

Springer Publishing Company

Access to resources Recommend Favorite